Sodium-glucose cotransporter 2 inhibitor (SGLT2i), which ameliorates hyperglycemia by suppressing renal glucose reabsorption in urine, has been demonstrated to have favorable effects on the kidney and cardiovascular outcomes in large clinical trials involving patients with T2DM [6–8]. Here, SLC5A2 is linked to type 2 diabetes mellitus.